Antonella Sistigu

List of Publications by Citations

Source: https://exaly.com/author-pdf/3606179/antonella-sistigu-publications-by-citations.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37 papers	5,481 citations	22 h-index	41 g-index
41 ext. papers	7,275 ext. citations	10 avg, IF	4.59 L-index

#	Paper	IF	Citations
37	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death and Differentiation*, **2018**, 25, 486-541	12.7	2160
36	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. *Nature Medicine*, **2014**, 20, 1301-9	50.5	596
35	Consensus guidelines for the detection of immunogenic cell death. *OncoImmunology*, **2014**, 3, e955691	7.2	524
34	An immunosurveillance mechanism controls cancer cell ploidy. *Science*, **2012**, 337, 1678-84	33.3	299
33	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. *Science*, **2015**, 350, 972-8	33.3	267
32	Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. *Cancer Research*, **2011**, 71, 768-78	10.1	240
31	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death **2020**, 8,		233
30	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. *Seminars in Immunopathology*, **2011**, 33, 369-83	12	217
29	Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. *Molecular and Cellular Oncology*, **2015**, 2, e1012976	1.2	95
28	CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. *Cancer Research*, **2014**, 74, 436-45	10.1	90
27	Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. *Journal of Immunology*, **2011**, 186, 5142-50	5.3	86
26	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. *OncoImmunology*, **2017**, 6, e1317420	7.2	84
25	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. *OncoImmunology*, **2017**, 6, e1314424	7.2	69
24	Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. *Cancer Journal (Sudbury, Mass.)*, **2011**, 17, 351-8	2.2	66
23	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. *Immunological Reviews*, **2017**, 280, 165-174	11.3	52
22	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. *Cytokine and Growth Factor Reviews*, **2017**, 36, 67-77	17.9	46
21	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. *Gut*, **2018**, 67, 903-917	19.2	45

20	IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. *Neoplasia*, **2012**, 14, 1223-35	6.4	41
19	A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. *Journal of Immunotoxicology*, **2014**, 11, 337-46	3.1	38
18	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. *Trends in Cell Biology*, **2019**, 29, 396-416	18.3	37
17	Replication stress response in cancer stem cells as a target for chemotherapy. *Seminars in Cancer Biology*, **2018**, 53, 31-41	12.7	23
16	Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. *Oncotarget*, **2016**, 7, 885-901	5.5	23
15	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. *Cancer Immunology Research*, **2018**, 6, 658-670	12.5	21
14	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. *OncoImmunology*, **2015**, 4, e988042	7.2	21
13	Macrophages transmit human immunodeficiency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9. *Journal of Virology*, **2007**, 81, 9078-87	6.6	20
12	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. *Frontiers in Immunology*, **2020**, 11, 2166	8.4	19
11	Trial watch - inhibiting PARP enzymes for anticancer therapy. *Molecular and Cellular Oncology*, **2016**, 3, e1053594	1.2	18
10	The added value of type I interferons to cytotoxic treatments of cancer. *Cytokine and Growth Factor Reviews*, **2017**, 36, 89-97	17.9	13
9	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. *Cell Death and Differentiation*, **2021**, 28, 2060-2082	12.7	10
8	Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells. *Journal of General Virology*, **2009**, 90, 2777-2787	4.9	6
7	The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. *Cells*, **2021**, 10,	7.9	6
6	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. *Cancers*, **2021**, 13,	6.6	4
5	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. *Cells*, **2020**, 9,	7.9	4
4	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. *Emerging Topics in Life Sciences*, **2017**, 1, 471-486	3.5	3
3	LTX-315, CAPtivating immunity with necrosis. *Cell Cycle*, **2016**, 15, 1176-7	4.7	3

2	Assessment of IFN-and granzyme-B production by in "sitro" technology. *Methods in Enzymology*, **2020**, 631, 391-414	1.7	2
1	Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. *Methods in Enzymology*, **2020**, 632, 39-54	1.7	